In Brief: Baxter
This article was originally published in The Gray Sheet
Executive Summary
Baxter: U.S. clinicals of the Edwards MIRA bileaflet mechanical heart valve are scheduled to begin in 1998, pending FDA approval of an investigational device exemption. The device, which received European CE mark approval on Dec. 9, features a new "sewing ring" design as well as technology from Baxter's Starr-Edwards silastic ball valve, and is "particularly suitable for a wide variety of surgical techniques, including...minimally invasive techniques," the company claims. The Edwards MIRA is manufactured by Fiat Group subsidiary Sorin Biomedica and will be marketed worldwide by Baxter under a 1996 agreement...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.